指南与共识妇科

子宫内膜癌辅助治疗指南的依从性:高危患者仍有改进空间

Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.
指南 / 共识 · Gynecol Oncol · 2017-05-25

该研究基于荷兰癌症登记处2005至2014年确诊的14564例子宫内膜癌患者数据,按风险组评估医生对辅助治疗指南的依从性。总体依从率为85%,低/中低危组最高(98%),高危组最低(61%),且高危组依从率从2005-2009年的64%降至2010-2014年的57%。结论认为低/中低危患者依从性极佳,高危患者仍有改进空间。

要点

  • 低/中低危患者指南依从性达98%,无辅助治疗指征。
  • 高危患者依从性最低(61%),且从64%降至57%。
  • 高危III期浆液性癌依从性为55%,从41%升至66%。

核心结论

  • 医生对低/中低危子宫内膜癌患者辅助治疗指南的依从性极佳,但高危患者仍有改进空间。
  • 正在进行的随机临床试验结果可能为高危子宫内膜癌患者的辅助治疗提供更明确的指导。

研究设计与样本

  • 基于荷兰癌症登记处的群体队列研究,纳入2005至2014年确诊、手术治疗后无残留肿瘤的子宫内膜癌患者,共14564例。
  • 按FIGO分期、分级、肿瘤类型和年龄将患者分层为风险组,评估依从性随时间的变化及其对生存的影响。

主要发现

  • 患者被分层为低/中低危(52%)、中高危(21%)和高危(20%)风险组。
  • 总体辅助治疗指南依从率为85%。
  • 低/中低危患者依从性最高(98%,无辅助治疗指征)。
  • 高危患者依从性最低(61%,有外照射放疗联合/不联合化疗指征),且从2005-2009年的64%降至2010-2014年的57%。
  • 高危FIGO III期浆液性疾病患者依从性为55%(有化疗联合/不联合放疗指征),从2005-2009年的41%升至2010-2014年的66%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Compliance of physicians with guidelines has emerged as an important indicator for quality of care. We evaluated compliance of physicians with adjuvant therapy guidelines for endometrial cancer patients in the Netherlands in a population-based cohort over a period of 10years. METHODS: Data from all patients diagnosed with endometrial cancer between 2005 and 2014, without residual tumor after surgical treatment, were extracted from the Netherlands Cancer Registry (N=14,564). FIGO stage, grade, tumor type and age were used to stratify patients into risk groups. Possible changes in compliance over time and impact of compliance on survival were assessed. RESULTS: Patients were stratified into low/low-intermediate (52%), high-intermediate (21%) and high (20%) risk groups. Overall compliance with adjuvant therapy guidelines was 85%. Compliance was highest in patients with low/low-intermediate risk (98%, no adjuvant therapy indicated). The lowest compliance was determined in patients with high risk (61%, external beam radiotherapy with/without chemotherapy indicated). Within this group compliance decreased from 64% in 2005-2009 to 57% in 2010-2014. In high risk patients with FIGO stage III serous disease compliance was 55% (chemotherapy with/without radiotherapy indicated) and increased from 41% in 2005-2009 to 66% in 2010-2014. CONCLUSION: While compliance of physicians with adjuvant therapy guidelines is excellent in patients with low and low-intermediate risk, there is room for improvement in high risk endometrial cancer patients. Eagerly awaited results of ongoing randomized clinical trials may provide more definitive guidance regarding adjuvant therapy for high risk endometrial cancer patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Eggink FA, Mom CH, Boll D, et al. Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients. Gynecol Oncol. 2017. PMID: 28552255. doi:10.1016/j.ygyno.2017.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。